nimorazole has been researched along with Squamous Cell Carcinoma of Head and Neck in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (88.89) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Baumann, M; Besso, MJ; Bitto, V; Koi, L; Krause, M; Kurth, I; Linge, A; Löck, S; Möbius, L; Overgaard, J; Pfeifer, M; Valentini, C; Weise, C; Yaromina, A; Zips, D | 1 |
| Bar-Deroma, R; Castadot, P; Christiaens, M; Collette, S; Giralt, J; Grant, W; Gregoire, V; Hurkmans, CW; Kazmierska, J; Monti, AF; Overgaard, J; Tomsej, M; Weber, DC | 1 |
| Alsner, J; Andersen, E; Andersen, LJ; Evensen, JF; Grau, C; Hansen, HS; Hoff, CM; Johansen, J; Lassen, P; Overgaard, J; Overgaard, M; Specht, L | 1 |
| Alsner, J; Busk, M; Horsman, MR; Olthof, N; Overgaard, J; Speel, EJ; Sørensen, BS | 1 |
| Frederiksen, KD; Metwally, MA; Overgaard, J | 1 |
| Baines, H; Bolton, S; Miles, E; Slevin, N; Thomson, D; West, C; Yang, H | 1 |
| Hassan Metwally, MA; Jansen, JA; Overgaard, J | 1 |
| Andersen, LJ; Bentzen, J; Eriksen, JG; Overgaard, J; Primdahl, H; Toustrup, K | 1 |
| Ali, R; Grau, C; Hassan Metwally, MA; Iqbal, K; Kuddu, M; Overgaard, J; Prasad, R; Shouman, T; Strojan, P | 1 |
5 trial(s) available for nimorazole and Squamous Cell Carcinoma of Head and Neck
| Article | Year |
|---|---|
Quality assurance of radiotherapy in the ongoing EORTC 1219-DAHANCA-29 trial for HPV/p16 negative squamous cell carcinoma of the head and neck: Results of the benchmark case procedure.
Topics: Benchmarking; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Humans; Nimorazole; Organs at Risk; Prospective Studies; Quality Assurance, Health Care; Radiotherapy Planning, Computer-Assisted; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck | 2017 |
DAHANCA 10 - Effect of darbepoetin alfa and radiotherapy in the treatment of squamous cell carcinoma of the head and neck. A multicenter, open-label, randomized, phase 3 trial by the Danish head and neck cancer group.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Darbepoetin alfa; Disease-Free Survival; Dose Fractionation, Radiation; Female; Head and Neck Neoplasms; Hemoglobins; Humans; Male; Middle Aged; Nimorazole; Oxygen; Patient Compliance; Radiation-Sensitizing Agents; Squamous Cell Carcinoma of Head and Neck | 2018 |
NIMRAD - a phase III trial to investigate the use of nimorazole hypoxia modification with intensity-modulated radiotherapy in head and neck cancer.
Topics: Antitrichomonal Agents; Carcinoma, Squamous Cell; Cell Hypoxia; Combined Modality Therapy; Head and Neck Neoplasms; Humans; Nimorazole; Radiation-Sensitizing Agents; Radiotherapy, Intensity-Modulated; Research Design; Squamous Cell Carcinoma of Head and Neck | 2014 |
Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Nimorazole; Squamous Cell Carcinoma of Head and Neck | 2015 |
IAEA-HypoX. A randomized multicenter study of the hypoxic radiosensitizer nimorazole concomitant with accelerated radiotherapy in head and neck squamous cell carcinoma.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Dose Fractionation, Radiation; Female; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Hypoxia; Male; Middle Aged; Neoplasm Staging; Nimorazole; Patient Compliance; Radiation-Sensitizing Agents; Squamous Cell Carcinoma of Head and Neck | 2015 |
4 other study(ies) available for nimorazole and Squamous Cell Carcinoma of Head and Neck
| Article | Year |
|---|---|
Prognostic biomarkers for the response to the radiosensitizer nimorazole combined with RCTx: a pre-clinical trial in HNSCC xenografts.
Topics: Chemoradiotherapy; Head and Neck Neoplasms; Heterografts; Humans; Hypoxia; Nimorazole; Prognosis; Squamous Cell Carcinoma of Head and Neck | 2023 |
Radiosensitivity and effect of hypoxia in HPV positive head and neck cancer cells.
Topics: Carcinoma, Squamous Cell; Cell Hypoxia; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p16; Head and Neck Neoplasms; Humans; Neoplasm Proteins; Nimorazole; Papillomaviridae; Radiation Tolerance; Squamous Cell Carcinoma of Head and Neck | 2013 |
Compliance and toxicity of the hypoxic radiosensitizer nimorazole in the treatment of patients with head and neck squamous cell carcinoma (HNSCC).
Topics: Adult; Aged; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Male; Medication Adherence; Middle Aged; Nimorazole; Radiation-Sensitizing Agents; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck | 2014 |
Study of the population pharmacokinetic characteristics of nimorazole in head and neck cancer patients treated in the DAHANCA-5 trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Nimorazole; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Squamous Cell Carcinoma of Head and Neck | 2015 |